RENISHAW NEURO SOLUTIONS LTD

Their core work

Renishaw Neuro Solutions is a UK medical device company specializing in precision drug delivery systems for the brain and central nervous system. They develop the hardware and delivery technology — catheters, robotic guidance systems, and implantable devices — that enables substances to be deposited at exact locations deep within brain tissue with minimal invasiveness. In EU projects, they function as the technology provider: clinical and academic partners design the therapy, while Renishaw Neuro Solutions supplies the engineering capability to actually get it into the patient's brain safely. Their parent company, Renishaw plc, is a global precision engineering firm, and this subsidiary focuses that engineering heritage entirely on neurosurgical applications.

What they specialise in

How they've shifted over time

Their earliest H2020 work (EDEN2020, from 2016) centered on the delivery platform itself — the surgical tools and ecosystem for getting into the brain safely and precisely. By 2017, with TreatER, the focus shifted from the device platform toward clinical validation: they were now enabling a real Parkinson's disease trial using a novel protein (CDNF) requiring intracerebral administration. This trajectory suggests a maturing product — moving from platform-building to proving clinical utility in specific disease indications. The progression from "neurosurgery tooling" toward "CNS disease treatment enablement" is a classic medtech arc from engineering to therapy.

They are moving from generic neurosurgical tooling toward disease-specific clinical applications, suggesting future collaborations will likely involve specific CNS indications — Parkinson's, Alzheimer's, or other conditions requiring targeted brain delivery — rather than platform-level engineering alone.

How they like to work

Renishaw Neuro Solutions has never led a consortium — in both projects they joined as a participant, contributing specialized device technology while others coordinated. This is consistent with their role as a hardware enabler: their value is the delivery device, not project management. Despite only two projects, they collaborated with 22 distinct partners across 10 countries, indicating they plug into large, complex consortia built around clinical trials and multi-site studies. For a prospective partner, this means they are experienced with large international projects but will expect to own a defined technical deliverable rather than taking broad coordination responsibilities.

With 22 unique partners across 10 countries from just 2 projects, their network density is high relative to their project count, pointing to large clinical consortia with hospitals, universities, and biotech firms across Europe. Their UK base and EU participation pre-Brexit suggests established relationships on the continent that likely persist despite the UK's changed Horizon status.

What sets them apart

Renishaw Neuro Solutions occupies a rare niche: a precision engineering company — not a pharma company, not a pure robotics firm — whose sole focus is enabling other organisations' therapies to physically reach the right spot in the brain. This makes them an indispensable partner for any clinical consortium developing intracerebral or intrathecal therapies that needs a credible, CE-mark-capable device partner. Their parent company's global quality and manufacturing infrastructure gives them a credibility and regulatory pathway that academic device builders cannot match.

Highlights from their portfolio

• TreatER
  The only project with confirmed EC funding (EUR 700,000), it represents a proof-of-concept clinical trial for CDNF — a genuinely novel neuroprotective protein — delivered directly into the brain, making it a high-stakes, first-in-human application of their delivery technology.
• EDEN2020
  A major platform-building effort spanning 2016–2021 with a Digital sector classification alongside Health, indicating the project combined robotics, imaging, and software with the physical delivery hardware — the broadest technical scope they have engaged in.